[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urologic-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urologic-disorders":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,92,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100561259","noninvasive-spinal-cord-stimulation-for-early-sci-100561259",false,"NCT06587841","Noninvasive Spinal Cord Stimulation for Early SCI","Noninvasive Spinal Cord Neuromodulation to Improve Lower Urinary Tract Function After Spinal Cord Injury in Ukrainian War Veterans","Inclusion Criteria:\n\n* A participant must meet all of the following criteria in order to be eligible to participate:\n\n  1. Be a resident of either British Columbia (for Vancouver Site) with an active provincial medical service plan or Ukraine (for Ukraine Site) Age between 19 and 65 years at the time of consent\n  2. Subacute (time since injury 3-6 months) or chronic (time since injury 12+ months) SCI\n  3. ASIA Impairment Scale (AIS) A or B at spinal segments C5-T10\n  4. Documented impaired LUT function\n  5. Women of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:\n\n     i. Women of childbearing potential must have a confirmed negative pregnancy test prior to the baseline visit.\n\n     ii. Women of childbearing potential must agree to use adequate contraception during the period of the trial and for at least 28 days after completion of treatment. Effective contraception includes abstinence.\n  6. Sexually active males with female partners of childbearing potential must agree to use effective contraception during the period of the trial and for at least 28 days after completion of treatment.\n  7. Must provide informed consent.\n  8. Agrees to comply with all planned visits and assessments, adhere with established bowel and LUT routines and refrain from initiation of new medications for bowel and LUT management without notifying the Principal Investigator of this study.\n\n     Exclusion Criteria:\n* A participant who meets any of the following criteria will be ineligible to participate:\n\n  1. Clinically significant depression with thoughts of suicidal ideation (PHQ-9 total score above 20) or debilitating PTSD (PCL-5 total score above) or as judged by the investigator.\n  2. History of bladder augmentation or continent or incontinent urinary stoma or prior bladder surgery.\n  3. Exhibits signs of lower motor neuron injury (i.e., concomitant conus medullaris\u002Fcauda equina injury).\n  4. History of intradetrusor or intrasphincter onabotulinumtoxinA injections within 9 months of baseline visit.\n  5. Concurrent use of any medication or treatment that in the opinion of the investigator interferes with study outcomes.\n  6. Presence of cognitive impairments, social\u002Fpsychological problems, or other comorbid conditions that, in the opinion of the Investigator, will preclude them from participation and completion of the study\n  7. Presence of severe acute medical issues that interfere with testing (e.g., stage 3\u002F4 pressure ulcers, uncontrolled diabetes).\n  8. Contraindications for TSCS, such as:\n\n     8.1. Implanted Cardiac pacemaker 8.2 Implanted metal in the trunk or spinal cord 8.3 Intrathecal delivery system (e.g., baclofen pump) 8.4 Implanted central or peripheral neuromodulator\n  9. Medical condition that may put the participant at risk as determined by the investigator.\n  10. Participation in or plans to participate in another research study that may interfere with the study endpoints.","ALL","19 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators are looking to determine the safety and efficacy of non-invasive transcutaneous spinal cord stimulation (TSCS) in promoting recovery of lower urinary tract (LUT), bowel, sexual, and cardiovascular function, as well as spasticity in individuals with subacute and chronic SCI (time since injury 3-6 months) and the impact on quality of life. The study will be conducted at two sites; site 1 in Canada and site 2 in the Ukraine. Up to 60 subjects will be enrolled; 10 adults at the ICORD, University of British Columbia (UBC), Vancouver, Canada site and 50 adults at the Rivne Regional War Veterans Hospital, Rivne, Ukraine. Eligible participants will be randomized (1:1 ratio) either to Group 1 (G1) or Group 2 (G2). G1 will receive therapeutic TSCS for 8 weeks (3 times per week; 1 hour per session) in conjunction with conventional rehabilitation (3-4 hours per day; 5 days per week). G2 will receive 8 weeks of sham stimulation in conjunction with conventional rehabilitation. After 8 weeks, G2 will cross over and receive therapeutic TSCS for 8 weeks, whereas G1 will continue to receive TSCS therapy for another 8 weeks, for a total of 16 weeks. Eligible participants enrolled into the study will attend fifty eight (58) visits for assessments, therapy, and follow-up. The expected duration of study participation for each participant will be 33 weeks.",[27,28,29,30,31],"Spinal Cord Injuries","Bowel Dysfunction","Sexual Dysfunction","Autonomic Dysfunction","Urologic Disorders","RECRUITING","2026-02-23",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":36},"2024-10-01",{"date":40,"type":21},"2027-10-01",{"name":42,"class":43},"University of British Columbia","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":69,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100583907","holistic-integration-for-healthy-longevity-and-aging-in-place-100583907","NCT06882434","Holistic Integration for Healthy Longevity and Aging in Place","Holistic Integration for Healthy Longevity and Aging in Place - Establishing Full-spectrum Community-based Care System for Older People to Maintain Wellbeing Pursuing Abilities","HIHOPE","Inclusion Criteria:\n\n* Age ≥55 years (includes older adults and pre-elderly individuals).\n* No severe functional disability (must be able to walk independently, use assistive devices, or operate a wheelchair independently).\n* No severe cognitive impairment (must be able to respond appropriately to verbal questions).\n\nExclusion Criteria:\n\n* Irregular community participation (less than once per week in the target community).\n* Mild dementia or greater (assessed during screening). If identified, family members will be notified, and they retain the right to withdraw the participant unconditionally.",true,"55 Years",{"count":56,"type":21},600,[24],"Background:\n\nTaiwan is experiencing rapid population aging, with a growing prevalence of chronic diseases and functional impairments among older adults. Existing Integrated Care for Older People (ICOPE) programs focus primarily on screening but lack sufficient follow-up and intervention. In response, the HI-HOPE Project was developed to establish a community-based, multidisciplinary intervention model to enhance intrinsic capacity and promote healthy aging in rural elderly populations.\n\nSurvey and Screening:\n\nThe study will be conducted in 30 community centers across Yunlin County, targeting older adults aged ≥55 years. Participants will undergo biannual screenings over two years, assessing cognitive function, depression, mobility, vitality (nutrition), hearing, vision, osteoporosis, polypharmacy, urological health, and social participation \\& welfare.\n\nIntervention:\n\nParticipants will be randomly assigned to either:\n\nHI-HOPE Integrated Care Group:\n\nOn-Site Community Interventions: Exercise training, mindfulness, social activities, oral and swallowing rehabilitation, hearing and vision training.\n\nTelehealth \\& Remote Education: Digital health monitoring, remote consultations, and health education.\n\nReferral Services: Access to specialized medical care, transportation assistance, and follow-up support.\n\nControl Group: Standard community care services without additional structured interventions.\n\nOutcome Measures:\n\nPrimary outcomes include changes in intrinsic capacity of functional health metrics, including abnormalities of I-COPE components (mobility, cognitive status, depression, hearing, vision, vitality) . Secondary outcomes assess quality of life, activities of daily living, hospitalization, emergency visits, falls, and mortality rates over two years.\n\nSignificance:\n\nThis project integrates digital health technologies, interdisciplinary care, and community-based interventions to improve elderly health outcomes. The findings will guide the future scalability of integrated aging care models in Taiwan and beyond.",[60,61,62,63,64,65,66,67,31,68],"Cognitive Decline","Sarcopenia","Depression Disorders","Nutrition Disorder","Swallowing Difficulties","Hearing Disorder","Visual Disorder","Osteoporosis","Polypharmacy",[51,70,71,72,73,74,75,76,77,78,79,80,81],"I-COPE","dementia","depression","dysphagia","nutrition","sarcopenia","frailty","hearing disorder","visual disorder","osteoporosis","urologic disorder","polypharmacy","NOT_YET_RECRUITING","2025-03-20",{"date":85,"type":36},"2025-03-25",{"date":87,"type":21},"2025-03-15",{"date":89,"type":21},"2028-12-31",{"name":91,"class":43},"National Taiwan University Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100581673","validation-of-the-short-form-of-the-lower-urinary-tract-symptoms-treatment-constraints-assessment-questionnaire-100581673","NCT06853366","Validation of the Short Form of the \"Lower Urinary Tract Symptoms Treatment Constraints Assessment\" Questionnaire","FC-LUTS-TCA","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Patients with central or peripheral neurological pathology, followed and managed for vesico-sphincter disorders\n* Patients receiving urinary treatment for more than 3 months\n* No therapeutic modification between D0 and D14 of the questionnaire\n* French-speaking patients (able to read, write and understand French)\n\nExclusion Criteria:\n\n* Minor patients (age ≤ 17 years)\n* Patients who have stopped urinary treatment\n* Patients with major cognitive impairment\n* Patients who speak little or no French\n* Patients who refused to participate in research, or who objected to the use of their data for research purposes","18 Years",{"count":101,"type":21},242,"OBSERVATIONAL","For many years, the evaluation of treatments has been a central issue in patient care. The various domains assessed have gradually evolved over time, ranging from satisfaction, improvement and quality of life, to the more recent introduction of the Patient Reported Outcome Measure (PROM). These questionnaires or measurement scales (PROMs) focus assessment on the patient and his or her direct experience. Statistical validation of numerous assessment tools has made it possible to quantify objectively many areas of assessment that were initially linked to the patient's feelings, and therefore to their subjectivity. Thus, improvement, quality of life, patient expectations and goal attainment have been the preferred areas for the development of these PROMs.\n\nHowever, certain areas have been sidelined in the creation of these tools. For example, the constraint of care or the side effects or negative effects of care have not been studied through specific means of evaluation.\n\nIn response to this shortcoming, we have developed a questionnaire specifically designed for neuro-urological treatments in a neurological patient population.\n\nThe LUTS-TCA (Lower Urinary Tract Symptoms Treatment Constraints Assessment) was developed in French and statistically validated in 2019.\n\nThe aim of the study is to create a short form of the LUTS TCA in French, in a population of neurological patients.\n\nThis short form, which would be easier to use and interpret, would simplify its use in everyday practice. Indeed, a large majority of neuro-urology patients suffer from neurodegenerative or progressive pathologies, marked by significant and disabling physical and psychological fatigue symptoms. Long-form questionnaires, or the addition of multiple assessment questionnaires during a single visit to the department, make overall assessment more complex.\n\nIn addition, this short-form questionnaire is presented in a slightly different form to the long-form version, showing several domains of constraint (physical, social, psychological and care system). This classification should simplify the interpretation and understanding of care constraint, by and for patients.\n\nFor the patient, the validation study will take place in 2 phases:\n\n* A first phase at the time of the consultation (Day 0): response to the questionnaires making up the study, i.e. the short form of the LUTS TCA (appendix 2), then the validated form of the LUTS TCA (22 questions) and finally the PGI (two questions).\n* A second phase, at a distance from the consultation (Day 14 post-consultation): response to the short form of the LUTS TCA (questionnaire handed out at the consultation, accompanied by a stamped envelope for return).",[31],"2025-02-25",{"date":107,"type":36},"2025-02-28",{"date":109,"type":36},"2025-02-20",{"date":111,"type":21},"2026-12-01",{"name":113,"class":43},"Centre Hospitalier de Saint-Denis",2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":53,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":127,"conditions":128,"keywords":138,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":44},"100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052","NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",{"count":123,"type":21},5000,[125,126],"PHASE1","PHASE2","This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[129,130,131,132,133,134,135,136,29,31,137],"Autoimmune Diseases","Cardiovascular Disorders","Diabetes Complications","Integumentary Disease","Musculoskeletal Disorders","Neurodegenerative Disorders","Neurologic Disorders","Pulmonary Disorders","Viral Illness",[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Neurodegenerative Diseases","Central Nervous System Diseases","Tauopathies","Brain Diseases","Dementia","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Nervous System Diseases","Alzheimer Disease","Musculoskeletal Diseases","Cardiovascular Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":168,"type":36},"2022-04-29",{"date":170,"type":36},"2020-07-09",{"date":172,"type":21},"2030-12-09",{"name":174,"class":175},"Thomas Advanced Medical LLC","INDUSTRY"]